**Table 4. State Counts for Synthetic Cannabinoid Substances: 2013**

*Counts of synthetic cannabinoid substances submitted to laboratories from January 1, 2013, through December 31, 2013*

| Drug | Alabama | Alaska | Arizona | Arkansas | California | Colorado | Connecticut | Delaware | District of Columbia | Florida | Georgia | Hawaii | Idaho |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5Br-UR-144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5Cl-UR-144 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| 5F-AB-PINACA | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| 5F-ADBICA | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5F-AKB48 | 1 | 0 | 1 | 9 | 4 | 12 | 0 | 0 | 0 | 16 | 57 | 0 | 0 |
| 5F-PB-22 | 13 | 0 | 9 | 105 | 3 | 46 | 13 | 0 | 0 | 127 | 58 | 8 | 5 |
| A-796260 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| A-834735 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A-836339 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| AB-001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AB-FUBINACA | 89 | 0 | 5 | 31 | 12 | 67 | 2 | 0 | 0 | 125 | 110 | 0 | 3 |
| AB-PINACA | 32 | 0 | 5 | 44 | 2 | 27 | 1 | 0 | 0 | 55 | 43 | 0 | 0 |
| ADB-PINACA | 0 | 0 | 0 | 0 | 0 | 35 | 0 | 0 | 0 | 0 | 34 | 0 | 0 |
| AKB48 | 1 | 0 | 0 | 7 | 0 | 14 | 0 | 0 | 0 | 2 | 3 | 0 | 0 |
| AM-1220 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| AM-1248 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-2233 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| AM-679 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-694 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM2201 | 34 | 0 | 17 | 17 | 21 | 31 | 23 | 15 | 3 | 50 | 92 | 0 | 6 |
| AM2201 benzimidazole analog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| BB-22 | 14 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| CB-13 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CP-47,497 C8 homolog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EAM-2201 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| FUB-PB-22 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| HU-210 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-211 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-308 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-018 (AM678) | 3 | 0 | 14 | 3 | 13 | 70 | 3 | 0 | 0 | 17 | 43 | 0 | 0 |
| JWH-018 adamantyl carboxamide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| JWH-019 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| JWH-022 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 8 | 0 | 0 |
| JWH-073 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-081 | 2 | 0 | 0 | 2 | 8 | 0 | 2 | 0 | 0 | 1 | 3 | 0 | 0 |
| JWH-122 | 19 | 0 | 1 | 4 | 3 | 1 | 5 | 11 | 3 | 11 | 28 | 0 | 0 |
| JWH-122 5-methylnapthyl isomer | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-203 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| JWH-210 | 4 | 0 | 1 | 5 | 1 | 0 | 1 | 0 | 0 | 7 | 25 | 0 | 0 |
| JWH-250 | 6 | 0 | 6 | 7 | 12 | 1 | 14 | 0 | 0 | 2 | 21 | 0 | 0 |
| JWH-251 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| JWH-302 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| MAM-2201 | 0 | 0 | 1 | 6 | 0 | 4 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| NNE1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| PB-22 | 49 | 1 | 1 | 47 | 1 | 36 | 4 | 0 | 0 | 255 | 42 | 6 | 0 |
| Pravadoline (WIN 48,098) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RCS-4 | 0 | 0 | 0 | 1 | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| RCS-4 C4 homolog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RCS-8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| STS-135 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 42 | 0 | 0 |
| Synthetic cannabinoids | 0 | 0 | 55 | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 113 |
| Synthetic cannabinoids (adamantoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (cyclopropanoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (naphthoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (phenylacetylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (quinolinylindolecarboxylates) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| UR-144 | 47 | 0 | 53 | 9 | 3 | 17 | 18 | 0 | 1 | 190 | 80 | 3 | 0 |

**Table 4. State Counts for Synthetic Cannabinoid Substances: 2013**

*Counts of synthetic cannabinoid substances submitted to laboratories from January 1, 2013, through December 31, 2013*

| Drug | Alabama | Alaska | Arizona | Arkansas | California | Colorado | Connecticut | Delaware | District of Columbia | Florida | Georgia | Hawaii | Idaho |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UR-144 N-heptyl analog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-597 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| URB-602 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-754 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| WIN 55,212-2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| XLR11 | 535 | 2 | 498 | 212 | 84 | 197 | 56 | 2 | 2 | 1,227 | 531 | 9 | 2 |
| XLR11 N-(2-fluoropentyl) isomer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| XLR11 N-(4-fluoropentyl) isomer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

| Drug | Illinois | Indiana | Iowa | Kansas | Kentucky | Louisiana | Maine | Maryland | Massachusetts | Michigan | Minnesota | Mississippi | Missouri |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5Br-UR-144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5Cl-UR-144 | 0 | 3 | 13 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| 5F-AB-PINACA | 0 | 8 | 2 | 23 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 22 |
| 5F-ADBICA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5F-AKB48 | 9 | 108 | 10 | 93 | 24 | 26 | 0 | 23 | 0 | 0 | 0 | 0 | 84 |
| 5F-PB-22 | 12 | 517 | 46 | 36 | 19 | 5 | 1 | 0 | 1 | 0 | 7 | 1 | 324 |
| A-796260 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A-834735 | 0 | 3 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A-836339 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AB-001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| AB-FUBINACA | 38 | 158 | 151 | 114 | 27 | 459 | 1 | 5 | 9 | 0 | 8 | 9 | 143 |
| AB-PINACA | 11 | 32 | 89 | 60 | 16 | 114 | 1 | 5 | 2 | 0 | 6 | 0 | 86 |
| ADB-PINACA | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AKB48 | 1 | 20 | 4 | 3 | 3 | 33 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| AM-1220 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-1248 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| AM-2233 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| AM-679 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-694 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM2201 | 88 | 56 | 23 | 43 | 19 | 2 | 0 | 14 | 5 | 37 | 25 | 15 | 51 |
| AM2201 benzimidazole analog | 0 | 0 | 7 | 3 | 0 | 19 | 0 | 0 | 3 | 0 | 0 | 0 | 2 |
| BB-22 | 0 | 0 | 1 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 |
| CB-13 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CP-47,497 C8 homolog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| EAM-2201 | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FUB-PB-22 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| HU-210 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-211 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-308 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-018 (AM678) | 14 | 20 | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 1 | 12 | 5 |
| JWH-018 adamantyl carboxamide | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| JWH-019 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| JWH-022 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| JWH-073 | 0 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| JWH-081 | 5 | 1 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| JWH-122 | 10 | 4 | 7 | 5 | 6 | 0 | 0 | 1 | 0 | 0 | 3 | 1 | 7 |
| JWH-122 5-methylnapthyl isomer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-203 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| JWH-210 | 2 | 6 | 3 | 3 | 4 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 4 |
| JWH-250 | 8 | 5 | 3 | 6 | 3 | 1 | 0 | 0 | 0 | 3 | 2 | 1 | 11 |
| JWH-251 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-302 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAM-2201 | 7 | 2 | 1 | 8 | 5 | 0 | 0 | 1 | 0 | 5 | 0 | 1 | 6 |
| NNE1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PB-22 | 0 | 0 | 97 | 67 | 56 | 16 | 0 | 17 | 4 | 0 | 25 | 0 | 205 |
| Pravadoline (WIN 48,098) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RCS-4 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| RCS-4 C4 homolog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RCS-8 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| STS-135 | 0 | 24 | 2 | 0 | 1 | 18 | 0 | 0 | 0 | 0 | 3 | 0 | 3 |
| Synthetic cannabinoids | 0 | 0 | 38 | 0 | 0 | 1,256 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Synthetic cannabinoids (adamantoylindoles) | 0 | 0 | 0 | 0 | 0 | 79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

**Table 4. State Counts for Synthetic Cannabinoid Substances: 2013**

*Counts of synthetic cannabinoid substances submitted to laboratories from January 1, 2013, through December 31, 2013*

| Drug | Illinois | Indiana | Iowa | Kansas | Kentucky | Louisiana | Maine | Maryland | Massachusetts | Michigan | Minnesota | Mississippi | Missouri |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synthetic cannabinoids (cyclopropanoylindoles) | 0 | 0 | 0 | 0 | 0 | 105 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (naphthoylindoles) | 0 | 0 | 0 | 0 | 0 | 111 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (phenylacetylindoles) | 0 | 0 | 0 | 0 | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (quinolinylindolecarboxylates) | 0 | 0 | 0 | 0 | 0 | 172 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| UR-144 | 71 | 190 | 10 | 26 | 29 | 83 | 0 | 59 | 1 | 0 | 11 | 0 | 79 |
| UR-144 N-heptyl analog | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-597 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-602 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| URB-754 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| WIN 55,212-2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| XLR11 | 647 | 1,277 | 444 | 705 | 274 | 799 | 5 | 857 | 13 | 0 | 45 | 2 | 919 |
| XLR11 N-(2-fluoropentyl) isomer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| XLR11 N-(4-fluoropentyl) isomer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

| Drug | Montana | Nebraska | Nevada | New Hampshire | New Jersey | New Mexico | New York | North Carolina | North Dakota | Ohio | Oklahoma | Oregon | Pennsylvania |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5Br-UR-144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5Cl-UR-144 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| 5F-AB-PINACA | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 5F-ADBICA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5F-AKB48 | 0 | 4 | 0 | 4 | 12 | 0 | 0 | 0 | 9 | 71 | 0 | 0 | 298 |
| 5F-PB-22 | 0 | 12 | 37 | 10 | 11 | 23 | 1 | 0 | 25 | 33 | 0 | 4 | 69 |
| A-796260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 7 |
| A-834735 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A-836339 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AB-001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AB-FUBINACA | 0 | 21 | 3 | 31 | 7 | 5 | 0 | 0 | 7 | 18 | 206 | 4 | 157 |
| AB-PINACA | 0 | 24 | 1 | 4 | 31 | 1 | 0 | 0 | 14 | 18 | 56 | 2 | 69 |
| ADB-PINACA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AKB48 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 9 | 66 | 16 | 0 | 8 |
| AM-1220 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-1248 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| AM-2233 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| AM-679 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-694 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 1 |
| AM2201 | 0 | 0 | 21 | 2 | 15 | 25 | 4 | 2 | 9 | 84 | 34 | 0 | 154 |
| AM2201 benzimidazole analog | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| BB-22 | 0 | 0 | 0 | 9 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CB-13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| CP-47,497 C8 homolog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| EAM-2201 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 2 |
| FUB-PB-22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-210 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-211 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-308 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-018 (AM678) | 0 | 0 | 23 | 1 | 11 | 0 | 0 | 2 | 2 | 14 | 0 | 7 | 3 |
| JWH-018 adamantyl carboxamide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| JWH-019 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 1 |
| JWH-022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-073 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| JWH-081 | 0 | 0 | 8 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 10 | 0 | 1 |
| JWH-122 | 0 | 0 | 3 | 0 | 6 | 5 | 0 | 0 | 7 | 7 | 6 | 0 | 21 |
| JWH-122 5-methylnapthyl isomer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| JWH-203 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| JWH-210 | 0 | 0 | 7 | 1 | 5 | 3 | 0 | 0 | 1 | 3 | 13 | 0 | 16 |
| JWH-250 | 0 | 0 | 8 | 0 | 0 | 2 | 0 | 0 | 0 | 4 | 11 | 0 | 7 |
| JWH-251 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-302 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAM-2201 | 0 | 1 | 1 | 0 | 6 | 2 | 0 | 0 | 7 | 0 | 2 | 0 | 52 |
| NNE1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PB-22 | 0 | 29 | 0 | 12 | 44 | 25 | 0 | 1 | 17 | 165 | 93 | 5 | 168 |
| Pravadoline (WIN 48,098) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |

**Table 4. State Counts for Synthetic Cannabinoid Substances: 2013**

*Counts of synthetic cannabinoid substances submitted to laboratories from January 1, 2013, through December 31, 2013*

| Drug | Montana | Nebraska | Nevada | New Hampshire | New Jersey | New Mexico | New York | North Carolina | North Dakota | Ohio | Oklahoma | Oregon | Pennsylvania |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCS-4 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 |
| RCS-4 C4 homolog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RCS-8 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| STS-135 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 2 |
| Synthetic cannabinoids | 3 | 1 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 11 |
| Synthetic cannabinoids (adamantoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (cyclopropanoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (naphthoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (phenylacetylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (quinolinylindolecarboxylates) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| UR-144 | 0 | 2 | 12 | 13 | 32 | 38 | 4 | 4 | 5 | 103 | 43 | 0 | 119 |
| UR-144 N-heptyl analog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-597 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-602 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| URB-754 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| WIN 55,212-2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| XLR11 | 0 | 54 | 177 | 137 | 296 | 77 | 10 | 63 | 142 | 1,226 | 1,128 | 17 | 1,172 |
| XLR11 N-(2-fluoropentyl) isomer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| XLR11 N-(4-fluoropentyl) isomer | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

| Drug | Rhode Island | South Carolina | South Dakota | Tennessee | Texas | Utah | Virginia | Virginia | Washington | West Virginia | Wisconsin | Wyoming |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5Br-UR-144 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5Cl-UR-144 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| 5F-AB-PINACA | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5F-ADBICA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 5F-AKB48 | 0 | 0 | 0 | 4 | 54 | 13 | 39 | 0 | 0 | 2 | 25 | 10 |
| 5F-PB-22 | 0 | 10 | 0 | 9 | 72 | 68 | 57 | 0 | 0 | 3 | 35 | 92 |
| A-796260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A-834735 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| A-836339 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AB-001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AB-FUBINACA | 0 | 3 | 0 | 5 | 190 | 2 | 15 | 0 | 5 | 1 | 42 | 3 |
| AB-PINACA | 0 | 3 | 0 | 13 | 90 | 23 | 0 | 0 | 2 | 4 | 22 | 15 |
| ADB-PINACA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| AKB48 | 0 | 2 | 0 | 0 | 15 | 4 | 7 | 0 | 0 | 5 | 0 | 0 |
| AM-1220 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-1248 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-2233 | 0 | 0 | 0 | 3 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 |
| AM-679 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| AM-694 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 0 | 0 | 0 | 0 | 0 |
| AM2201 | 0 | 5 | 0 | 34 | 80 | 55 | 36 | 0 | 5 | 16 | 30 | 10 |
| AM2201 benzimidazole analog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| BB-22 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CB-13 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| CP-47,497 C8 homolog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EAM-2201 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| FUB-PB-22 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-210 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-211 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HU-308 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-018 (AM678) | 2 | 0 | 0 | 8 | 12 | 28 | 26 | 0 | 0 | 1 | 8 | 3 |
| JWH-018 adamantyl carboxamide | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-019 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| JWH-022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-073 | 2 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 7 | 0 |
| JWH-081 | 1 | 0 | 0 | 3 | 2 | 3 | 2 | 0 | 0 | 1 | 4 | 0 |
| JWH-122 | 0 | 2 | 0 | 5 | 11 | 13 | 7 | 0 | 2 | 6 | 7 | 0 |
| JWH-122 5-methylnapthyl isomer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-203 | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 3 | 2 |

**Table 4. State Counts for Synthetic Cannabinoid Substances: 2013**

*Counts of synthetic cannabinoid substances submitted to laboratories from January 1, 2013, through December 31, 2013*

| Drug | Rhode Island | South Carolina | South Dakota | Tennessee | Texas | Utah | Virginia | Virginia | Washington | West Virginia | Wisconsin | Wyoming |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JWH-210 | 0 | 1 | 0 | 0 | 7 | 10 | 5 | 0 | 1 | 6 | 7 | 0 |
| JWH-250 | 1 | 1 | 0 | 13 | 12 | 12 | 2 | 0 | 0 | 0 | 3 | 0 |
| JWH-251 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| JWH-302 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAM-2201 | 0 | 0 | 0 | 1 | 16 | 9 | 3 | 0 | 0 | 0 | 4 | 0 |
| NNE1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PB-22 | 1 | 33 | 0 | 26 | 219 | 36 | 93 | 0 | 1 | 2 | 31 | 34 |
| Pravadoline (WIN 48,098) | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RCS-4 | 0 | 0 | 0 | 7 | 2 | 2 | 2 | 0 | 0 | 0 | 9 | 0 |
| RCS-4 C4 homolog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| RCS-8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| STS-135 | 0 | 0 | 0 | 1 | 0 | 0 | 7 | 0 | 0 | 1 | 0 | 0 |
| Synthetic cannabinoids | 0 | 0 | 12 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (adamantoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (cyclopropanoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (naphthoylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (phenylacetylindoles) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synthetic cannabinoids (quinolinylindolecarboxylates) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| UR-144 | 0 | 6 | 0 | 16 | 314 | 60 | 83 | 0 | 3 | 5 | 24 | 2 |
| UR-144 N-heptyl analog | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-597 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-602 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| URB-754 | 0 | 0 | 0 | 1 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| WIN 55,212-2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| XLR11 | 2 | 113 | 0 | 133 | 3,041 | 565 | 612 | 0 | 26 | 42 | 219 | 182 |
| XLR11 N-(2-fluoropentyl) isomer | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| XLR11 N-(4-fluoropentyl) isomer | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

*5Br-UR-144=[1-(5-Bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone*
*5Cl-UR-144=1-(5-Chloropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone*
*5F-AB-PINACA=N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide*
*5F-ADBICA=N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide*
*5F-AKB48=N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide*
*5F-PB-22=Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate*
*A-796260=[1-(2-Morpholinoethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone*
*A-834735=1-[(Tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)methanone*
*A-836339=N-[3-(2-Methoxyethyl)-4,5-dimethylthiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-carboxamide*
*AB-001=1-Pentyl-3-(1-adamantoyl)indole*
*AB-FUBINACA=(N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide*
*AB-PINACA=N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide*
*ADB-PINACA=N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide*
*AKB48=N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide*
*AM-1220=[1-[(1-Methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-1-naphthalenyl-methanone*
*AM-1248=1-[(N-Methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole*
*AM-2233=1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole*
*AM-679=1-Pentyl-3-(2-iodobenzoyl)indole*
*AM-694=1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole*
*AM2201=1-(5-Fluoropentyl)-3-(1-naphthoyl) indole*
*AM2201 benzimidazole analog=1-(5-Fluoropentyl)-1H-benzimidazol-2-yl)(naphthalene-1-yl)methanone*
*BB-22=1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid*
*CB-13=1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone*
*CP-47,497 C8 homolog=5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl]-phenol)*
*EAM-2201=1-(5-Fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole*
*FUB-PB-22=Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate*
*HU-210=(6aR,10aR)-3-(1,1'-dimethylheptyl)-6a,7,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol*
*HU-211=(6aS,10aS)-3-(1,1'-dimethylheptyl)-6a,7,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol*
*HU-308=4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-methanol*
*JWH-018 (AM678)=1-Pentyl-3-(1-naphthoyl)indole*
*JWH-018 adamantyl carboxamide=N-(Adamantan-1-yl)-1-pentyl-1H-indole-3-carboxamide*
*JWH-019=1-Hexyl-3-(1-naphthoyl)indole*
*JWH-022=1-(4-Pentenyl)-3-(1-naphthoyl)indole*
*JWH-073=1-Butyl-3-(1-naphthoyl)indole*
*JWH-081=1-Pentyl-3-(1-(4-methoxynaphthoyl) indole*
*JWH-122=1-Pentyl-3-(4-methyl-1-naphthoyl) indole*
*JWH-122 5-methylnapthyl isomer=1-Pentyl-3-(5-methyl-1-naphthoyl)indole*
*JWH-200=1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole*
*JWH-203=1-Pentyl-3-(2-chlorophenylacetyl) indole*

**Table 4. State Counts for Synthetic Cannabinoid Substances: 2013**

*Counts of synthetic cannabinoid substances submitted to laboratories from January 1, 2013, through December 31, 2013*

*JWH-210=1-Pentyl-3-(4-ethyl-1-naphthoyl)indole*
*JWH-250=1-Pentyl-3-(2-methoxyphenylacetyl) indole*
*JWH-251=1-Pentyl-3-(2-methylphenylacetyl)indole*
*JWH-302=1-Pentyl-3-(3-methoxyphenylacetyl)indole*
*MAM-2201=1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole*
*NNE1=1-Pentyl-N-(naphthalene-1-yl)-1H-indole-3-carboxamide*
*PB-22=Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate*
*Pravadoline (WIN 48,098)=3-(4-methoxyphenyl)-2-methyl-1-[(2-(4-morpholinyl)ethyl)-1H-indol-3-yl]-methanone*
*RCS-4=1-Pentyl-3-[4(-methoxy)-benxoyl] indole*
*RCS-8=1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole*
*STS-135=N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide*
*UR-144=(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone*
*UR-144 N-heptyl analog=(1-Heptyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone*
*URB-597=(3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-cyclohexyl-carbamate*
*URB-602=[1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester*
*URB-754=6-Methyl-2-(p-tolylamino)-4H-benzo[d][1,3]oxazin-4-one*
*WIN 55,212-2=[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone*
*XLR11=[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone*
*XLR11 N-(2-fluoropentyl) isomer=[1-(2-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone*
*XLR11 N-(4-fluoropentyl) isomer=[1-(4-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone*

**Methodology:** A summary of the NFLIS estimation methodology can be found in the NFLIS Methodology Summary publication at https://www.nflis.deadiversion.usdoj.gov/Reports.aspx. Additional details about the NFLIS data may be found in the Questions and Answers document at https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLISPublicDataQA.pdf.
**Source:** U.S. Drug Enforcement Administration, Diversion Control Division, National Forensic Laboratory Information System, 2013. Data generated: August 9, 2017.

**Suggested Citation:** U.S. Drug Enforcement Administration, Diversion Control Division. (2017). *Table 4. State counts for synthetic cannabinoid substances: 2013* . Retrieved from the NFLIS Public Resource Library at https://www.nflis.deadiversion.usdoj.gov/Resources/NFLISPublicResourceLibrary.aspx